7d agoInvestors.comBEARISH 38Earnings
Why This Top-Notch Trio Of Biotech Stocks Just Took A Tumble
Top-notch biotech stocks TG Therapeutics and Twist Bioscience took a tumble Monday on mixed second-quarter reports.
Archived explainer. For the current picture see today's TGTX page.
Why Is TG THERAPEUTICS INC (TGTX) Stock Down Today?
By the Top Tier Newswire AI Desk · August 3, 2026 at 9:50 AM ET · reviewed against 9 wire stories
TG THERAPEUTICS INC (TGTX) is down -8.05% in the latest session. Our newswire has captured 9 stories on TGTX across 8 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
TGTX stock fell 8.05% to $47.84 in early trading on Monday, driven by mixed second-quarter results that included a revenue beat and an EPS miss. The biotech company raised its 2026 revenue guidance following strong performance from its Briumvi drug, but the market reacted negatively to the earnings shortfall. The stock opened at $52.05 and fell to a session low of $47.50 before closing the session at $47.66.
What Happened
TG Therapeutics reported second-quarter 2026 financial results that included GAAP earnings per share of $0.05, which missed the expected $0.33. Revenue, however, came in at $240.34 million, exceeding estimates by $10.55 million and reflecting 70% year-over-year growth. The company raised its 2026 total global revenue target to approximately $950 million, up from $925 million previously, citing strong Briumvi sales and progress in late-stage clinical programs. Despite these positive developments, the earnings miss led to a sharp sell-off in the stock.
The CEO of TG Therapeutics stated that Briumvi is on track to become a $1 billion U.S. drug, but retail traders appeared unfazed by the earnings miss. The company also highlighted record quarterly performance and expanded programs for Briumvi, which contributed to the raised revenue guidance.
What The Data Shows
TGTX traded at a volume of 0.7 million shares, which is 0.3 times the 3-month daily average. The stock opened at $52.05 and reached a high of $53.50 before declining sharply. The 52-week range is $25.28 to $59.30, and the stock has fallen 2.7% over the last eight sessions, from $53.27 to $51.81. The stock’s fundamentals show a market cap of $7.4 billion, a P/E ratio of 18.1, and a net margin of 66.0%. Revenue has grown by 81.3% in the trailing twelve months.
What To Watch
TG Therapeutics has no scheduled earnings in the immediate future. Investors should monitor the breadth of coverage and market sentiment as the company continues to advance its clinical pipeline and expand Briumvi’s commercial reach.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TGTX by the numbers
Last: $47.84Session: -8.05%7 sessions: -15.03%Coverage: 9 stories / 8 sourcesAI sentiment: 57/100 (mixed)Mkt cap: $7.4BP/E: 18.152w: $25.28 to $59.30
The headlines behind the move
7d agoStocktwits NewsBULLISH 63Product/PR
TG Therapeutics CEO Says Briumvi Is On Track To Become A $1B US Drug – Retail Shrugs Off EPS Miss
The biotech firm increased its 2026 total global revenue target to around $950 million, up from $925 million previously.
7d agoInvestorsHubBULLISH 71Earnings
TG Therapeutics Raises 2026 Outlook Following Strong Briumvi Sales Growth
TG Therapeutics raised its 2026 revenue guidance after strong Briumvi sales drove second-quarter revenue growth, while the company also advanced multiple late-stage clinical programs.
7d agoInvesting.com MarketsBEARISH 42General
Why is TG Therapeutics stock sliding today?
Why is TG Therapeutics stock sliding today?
7d agoMarketChameleonBULLISH 73Earnings
TG Therapeutics Lifts 2026 Revenue Targets as BRIUMVI Momentum Accelerates—Key Data and Outlook
TG Therapeutics raised its full-year 2026 revenue guidance—and now targets BRIUMVI U.S. net product revenues near $900 million—after another record quarter. The strong clinical pipeline progress and expanded programs for myasthenia gravis and schizophrenia signal a broader growth story for TGTX shareholders.
7d agoSEC 8-KNEUTRAL 50General
TG THERAPEUTICS, INC. (TGTX) files 8-K
Filed: 2026-08-03 AccNo: 0001437749-26-025304 Size: 360 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
7d agoSeeking AlphaBULLISH 56Earnings
TG Therapeutics GAAP EPS of $0.05 misses by $0.26, revenue of $240.34M beats by $10.55M
TG Therapeutics (TGTX) Q2 2026 earnings: GAAP EPS miss, revenue up 70% and beat; raises 2026 BRIUMVI and global revenue outlook.
7d agoStockTitanBULLISH 67Earnings
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance
Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million Raises full year 2026 total global revenue target to approximately $950 million and raises...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on TGTX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier TGTX move explainers: 2026-08-04 · 2026-08-03 · 2026-07-13